Skip to content

About
Our Science
Research and Development
News
Careers and Culture

Menu

About
Our Science
Research and Development
News
Careers and Culture

News and Events

September 27, 2024

Cardurion Pharmaceuticals Selected as an Endpoints 11 Most Promising Biotech Company

September 26, 2024

Cardurion Pharmaceuticals Appoints Ron Renaud to Board of Directors

July 16, 2024

Cardurion Pharmaceuticals Announces $260 Million Series B Financing to Advance Its Pipeline of Innovative Medicines for Cardiovascular Diseases

May 13, 2024

Cardurion Pharmaceuticals Presents Positive Clinical Results from CARDINAL‑HF Phase 2a Clinical Trial of PDE9 Inhibitor in Patients With Heart Failure

November 7, 2023

Cardurion Pharmaceuticals to Provide Update on CaMKII Inhibitor Program at the American Heart Association’s Scientific Sessions 2023

October 4, 2023

Cardurion Pharmaceuticals Welcomes Emma Reeve as Independent Board Director and Audit Chair

April 19, 2023

Cardurion Pharmaceuticals Further Bolsters Leadership Team with Appointment of Stephen Migausky as General Counsel

January 19, 2023

Cardurion Pharmaceuticals Bolsters Leadership Team with Appointment of Elizabeth Radcliffe as Chief Financial Officer

September 21, 2022

Cardurion Pharmaceuticals Announces Dosing of Patients in CARDINAL-HF, a Phase 2 Clinical Trial of its PDE9 inhibitor in Heart Failure

Media and Investor Contact Information

To request additional information or contact us, please email: info@cardurion.com.

Contact Us
Privacy Policy
Terms of Use

Contact Us
Privacy Policy
Terms of Use

©2024 Cardurion Pharmaceuticals. All rights reserved.

This site uses cookies and third-party scripts to provide certain services. View Privacy Policy

Skip to content